Scientists have identified nanoparticles that latch onto and destroy virus membranes, opening new possibilities for antiviral ...

The antiviral combination of nirmatrelvir and ritonavir (brand name Paxlovid) is an effective treatment for people with COVID ...

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...

Collaboration with South Korean university advocates early antiviral treatment for hepatitis B | Feb. 5, 2025 13:09 ...

A new way to neutralize coronavirus and other membrane-surrounded viruses has been discovered by researchers from the Swedish ...

New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

The Sudan virus, a close relative of Ebola, has a fatality rate of 50% but remains poorly understood in terms of how it infects cells. Currently, no approved treatments exist.

new, more sensitive, rapid and inexpensive tests are necessary for the development of a cost-effective test-treatment strategy for influenza. The stockpile of antivirals (e.g., oseltamivir ...

The Sudan virus, a close relative of Ebola, has a fatality rate of 50% but remains poorly understood in terms of how it ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...